Core Viewpoint - The stock of Basilea Pharmaceutica (02616) has risen over 5%, currently at 6.07 HKD, following the announcement that its RET inhibitor, Pralsetinib (100 mg), has been included in the latest National Medical Insurance Drug List in China, effective January 1, 2026 [1] Company Developments - Basilea has successfully advanced four innovative drugs to market approval, with three of these products having completed clinical trials and registration in China, now included in the national medical insurance list [1] - The inclusion of Pralsetinib in the insurance list is expected to accelerate its market penetration, as noted in a report by Tianfeng Securities published in August [1] Pipeline and Technology - The company's preclinical pipeline includes over nine potential candidates, focusing on FIC/BIC research across oncology, autoimmune, and inflammatory diseases [1] - Basilea's innovative internal ADC technology platform features proprietary linkers designed to enhance the selective release of effective payloads in tumors, supporting multiple ADC products in its pipeline 2.0, which is expected to provide ongoing momentum for the company's future growth [1]
港股异动 基石药业-B(02616)涨超5% 普拉替尼获纳入国家医保目录 公司2.0管线矩阵持续扩大